에 대한 최신 뉴스 Tamboran Resources (NYSE:TBN) 주식

Tamboran Resources

Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.

Large Cap

News

Movers

Trading Ideas

MRNA

NTES

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SNOW

이들 8개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 탐보란 리소시스(NYSE:TBN)의 주식은 지난주 13.84% 하락했다.

스노우플레이크 및 JD닷컴 지난주 최악의 성과를 보인 8개 대형주 중 일부 (8월 18일-8월 24일)

COHR

CVNA

DELL

DKNG

MRVL

NVDA

SBUX

SMCI

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 9월 9일부터 치폴레 멕시칸 그릴(NYSE:CMG)의 CEO 겸 회장인 브라이언 니콜(Brian Niccol)이 스타벅스(NASDAQ:SBUX)의 새로운 회장 겸 CEO로 임명되었다고 발표한 후 스타벅스의 주가는 24.08% 상승했다.

엔비디아, 스타벅스 및 델은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 11일-8월 17일)

Tamboran Resources Corporation Common stock

Tamboran Resources Corp

TACHIBANA ELETECH CO LTD by TACHIBANA ELETECH CO LTD

Tachibana Eletech Co Ltd

PT BUKIT ASAM PER TBK ADR by PT Bukit Asam Persero TBK

PT Bukit Asam Tbk

Territorial Bancorp Inc

TAMBORAN RES LTD S/ADR by TAMBORAN RES LTD.

Tamboran Resources Corp Chess Depository Interests

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively with the Q1 2024 10-Q, Q2 2024 10-Q and Q3 2024 10-Q, the "Delinquent Filings"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously announced, the Company received earlier notices of non-compliance with respect to the Rule on August 20, 2024, May 17, 2024 and April 2, 2024 because it had not yet filed its Q2 2024 Form 10-Q, Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.
This Notice has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.
As previously disclosed on October 7, 2024, the Company intended to appeal a determination by the Nasdaq Listing Qualifications Department to delist the Company's securities due to the Company's Delinquent Filings. On October 8, 2024, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. The hearing is scheduled for November 26, 2024 and the request for the automatic stay of suspension was granted.
The Company is working diligently to complete its Delinquent Filings and will provide an update once more information is available.

LUNA

Luna Innovations Receives Additional Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q; Hearing Is Scheduled For November 26, 2024 And The Request For The Automatic Stay Of Suspension Was Granted

Barrington Research analyst Kevin Steinke maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and raises the price target from $17 to $18.

Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$3.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$3.5 Price Target

Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or the "Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America PBC ("Danone") to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed today with the U.S. Securities and Exchange Commission disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.
On November 5, 2024, Lifeway announced that its Board of Directors (the "Board") had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the Company and its shareholders and other stakeholders.
Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders and other stakeholders.
The Company does not undertake any obligation to provide any updates with respect to this or any other proposal or transaction, except as required under applicable law.
Lifeway shareholders do not need to take any action at this time.
Evercore is serving as a financial advisor to Lifeway and Sidley Austin LLP is serving as legal counsel to Lifeway.

LWAY

Lifeway Foods Confirms Receipt Of Revised, Unsolicited, Non-Binding Proposal From Danone  To Acquire All Outstanding Shares Of Common Stock Of Lifeway It Does Not Already Own For $27.00 Per Share In Cash

Generation Income (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIPR#NASDAQ">GIPR</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $2.26 million by 6.21 percent. This is a 30.17 percent increase over sales of $1.84 million the same period last year.

Earnings Beats

GIPR

Generation Income Q3 FFO $(0.03), Same YoY, Sales $2.40M Beat $2.26M Estimate

Shareholders Approve Waiver Of 19.99% Limit To Enable Additional Stock Issuance

Stock Split

LUXH

LuxUrban Hotels Announces 1-For-70 Reverse Stock Split Effective Nov. 20 To Strengthen Nasdaq Compliance

Commodity Roundup: Gold dips as focus shifts to Powell, oil rises on supply woes

Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range.

Ardent Health Slips After Downsized IPO

There's a lot to be optimistic about in the Energy sector as 3 analysts just weighed in on Permian Resources (PR – Research Report), Schlumberger (...

Analysts Offer Insights on Energy Companies: Permian Resources (PR), Schlumberger (SLB) and Tamboran Resources Corporation (TBN)

Tamboran Resources Corporation (TBN) has received a new Buy rating, initiated by Citi analyst, Paul Diamond CFA. Paul Diamond CFA has given his Buy...

Buy Rating on Tamboran Resources: High Reward Prospect Amid Operational Uncertainties

Companies in the Energy sector have received a lot of coverage today as analysts weigh in on Tamboran Resources Corporation (TBN – Research Report)...

Analysts Offer Insights on Energy Companies: Tamboran Resources Corporation (TBN) and Whitecap Resources (OtherSPGYF)

In a report released on October 10, Scott Hanold from RBC Capital maintained a Hold rating on Tamboran Resources Corporation (TBN – Research Report...

RBC Capital Sticks to Its Hold Rating for Tamboran Resources Corporation (TBN)

In a report released yesterday, Scott Hanold from RBC Capital maintained a Hold rating on Tamboran Resources Corporation (TBN – Research Report), w...

Tamboran Resources Corporation (TBN) Receives a Rating Update from a Top Analyst

Tamboran Resources GAAP EPS of -$0.42

Tamboran Resources Corporation ( ($TBN) ) has released its Q1 earnings. Here is a breakdown of the information Tamboran Resources Corporation prese...

Tamboran Resources Reports Q3 Financial Performance

Baupost's top Q3 trades include Jazz exit, new Dollar General stake

ALMS

ARDT

ARTV

CEIX

CLNE

CORN

CPER

GDXJ

GOOG

JAZZ

NUGT

PALL

PHYS

PSLV

QMMM

SOYB

SPGYF

TBPH

TWFG

VIVK

WBTN

WEAT

Press Releases

Tamboran Prices US IPO at US$24.00 Per Share

Tamboran Announces Partial Exercise of Underwriters' Over-Allotment Option

EP 98 Operational Update: Tamboran Commence Shenandoah South Pilot Project drilling program

Tamboran Schedules Fourth Quarter and FY24 Earnings Release and Webcast

Tamboran Schedules 1Q FY25 Earnings Release and Webcast

LBRT

Amplify Energy

Battalion Oil

Berry Corp

Cross Timbers Royalty

VAALCO Energy

Empire Petroleum Corporation Common Stock

Empire Petroleum

Evolution Petroleum Corporation, Inc. Common Stock

Evolution Petroleum

Greenfire Resources

GeoPark

Gran Tierra Energy

MV Oil Trust Units of Beneficial Interests

MV Oil

Permian Basin Royalty

PEDEVCO

PHX Minerals

PrimeEnergy Resources Corporation - Common Stock

PrimeEnergy Resources

PermRock Royalty Trust

Permianville Royalty

Ring Energy

Riley Exploration Permian, Inc. Common Stock

Riley Exploration Permian

SandRidge Energy

San Juan Basin Royalty Trust Common Stock

San Juan Basin Royalty

TXO Partners, L.P. Common Units Representing Limited Partner Interests

TXO Partners

US Energy

VOC Energy Trust Units of Beneficial Interest

VOC Energy

W&T Offshore

RBC Capital

Citigroup

Piper Sandler

이들 8개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 탐보란 리소시스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBN#NYSE">TBN</a>)의 주식은 지난주 13.84% 하락했다.
2. 골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주식은 12.37% 하락했다. 최근 금 광산 부문에서 <a href="https://www.benzinga.com//node/40424535" target="_blank" rel="noreferrer noopener">M&amp;A 활동</a>이 있었다.
3. 스노우플레이크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)가 2분기 실적을 보고한 후 주가는 10.82% 하락했고 몇몇 분석가들은 <a href="https://www.benzinga.com//node/40511947" target="_blank" rel="noreferrer noopener">주가 목표를</a> 낮췄다.
4. 넷이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>)가 예상보다 나쁜 <a href="https://www.benzinga.com//node/40502799" target="_blank" rel="noreferrer noopener">2분기 매출 실적</a>을 보고한 후 주가는 9.30% 하락했다.
5. 프랭클린 리소시스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>)는 최고 투자 책임자(CIO)인 켄 리치(Ken Leech)의 <a href="https://www.benzinga.com//node/40497028" target="_blank" rel="noreferrer noopener">휴직</a>으로 인해 마이클 뷰캐넌(Michael Buchanan)이 새로운 CIO로 임명되었다고 발표한 후 주가는 8.12% 하락했다.
6. JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)(징동닷컴)의 주식은 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)가 이 <a href="https://www.benzinga.com//node/40531142" target="_blank" rel="noreferrer noopener">회사의 지분을 매각할 계획을 발표</a>한 후 7.74% 하락했다.
7. 테무의 모기업인 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주가는 중국 중앙은행이 1년 및 5년 대출 우대금리를 각각 3.35%와 3.85%로 동결한 후 지난주 7.18% 하락했다. 주식은 또한 2분기 실적을 앞두고 <a href="https://www.benzinga.com//node/40532929" target="_blank" rel="noreferrer noopener">매도 압박</a>에 직면했다.
8. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 <a href="https://www.benzinga.com//node/40528702" target="_blank" rel="noreferrer noopener">5.77%</a> 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%a4%8c-%eb%b9%84%eb%94%94%ec%98%a4-%eb%b0%8f-%ed%83%80%ea%b9%83%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-11%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">줌 비디오 및 타깃은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li><a href="https://www.benzinga.com//node/40338228" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">9월 9일부터</a> 치폴레 멕시칸 그릴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)의 CEO 겸 회장인 브라이언 니콜(Brian Niccol)이 스타벅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)의 새로운 회장 겸 CEO로 임명되었다고 발표한 후 스타벅스의 주가는 24.08% 상승했다.</li>
<li>슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 소로스 펀드 매니지먼트(Soros Fund Management)가 SEC 양식 13F 제출에 슈퍼 마이크로의 주식 <a href="https://www.benzinga.com//node/40403528" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">24,898</a>주를 매입했음을 밝힌 후 23.06% 급등했다.</li>
<li>델 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) 주식은 <a href="https://www.benzinga.com//node/40400328" target="_blank" rel="noreferrer noopener">분석가들의 목표 주가 상향 조정하자</a> 20.72% 상승했다.</li>
<li>씨 리미티드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) 주식은 18.42% 상승했다. 이 회사가 2분기 실적을 발표했고, 몇몇 분석가들이 이 주식에 대한 <a href="https://www.benzinga.com//node/40377351" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했기 때문이다.</li>
<li>카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)의 주식은 17.55% 상승했다. 지난주 7월 자동차 판매 증가에 따른 자동차 관련주 상승세 때문이다.</li>
<li>울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식은 17.43% 뛰었다. 이번 주 버크셔 해서웨이(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/brk" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BRK" data-google-interstitial="false">BRK</a>)가 <a href="https://www.benzinga.com//node/40402528" target="_blank" rel="noreferrer noopener">이 회사의 지분을 추가한 뒤 </a>주가가 상승했다.</li>
<li>엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 주식은 지난주 17.19% 상승했다. 금리 인하로 이어질 수 있는 예상보다 부진한 생산자물가지수(PPI) 수치에 따른 전반적인 시장 강세 속에 반도체 주가 상승했다.</li>
<li>마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주식은 지난주 17.19% 상승했다.금리 인하로 이어질 수 있는 예상보다 부진한 생산자물가지수(PPI) 수치에 따른 전반적인 시장 강세 속에 반도체 주가 상승했다.</li>
<li>노무라 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMR#NYSE">NMR</a>)의 주식은 지난주 14.48% 상승하였다.</li>
<li>코히런트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>)의 주식은 14.02% 상승했다. 이 회사가 4분기 재무결과를 예상보다 좋게 발표하고, 분석가들이 <a href="https://www.benzinga.com/quote/COHR/analyst-ratings" target="_blank" rel="noreferrer noopener">이 주식에 대한 목표 주가를 상향 조정</a>했기 때문이다.</li>
</ol>
관련 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%ec%b9%98%ed%8f%b4%eb%a0%88%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">리비안과 치폴레는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 11일-8월 17일)</a></li>
</ul>
Image via Nvidia Blog
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Tamboran Resources

뉴스

에 대한 최신 뉴스 Tamboran Resources (NYSE:TBN) 주식

일요일, 8월 25, 2024

일요일, 8월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌